Alarmed by one of our gynecologists who argued that our HER2 positivity rate of 9% of breast tumors (DIN1C-3, invasive carcinoma) was too low in contrast to most of the data presented in the literature (18-20%) [5,9,10], this researcher designed a study to reassess the routinely determined immunohistochemical HER2 status and to compare the immunohistochemical results with the gold standard dual color FISH, using PNBSs. The gene discussed is ERBB2; the disease is invasive carcinoma.